

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 5

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

SUB  
H1 } 37. A purified non-hamster antibody or portion thereof that binds to a polypeptide consisting of SEQ ID NO:2.

38. The antibody or portion thereof of claim 37, wherein the antibody is monoclonal.

39. The antibody or portion thereof of claim 37, wherein the antibody is polyclonal.

40. The antibody or portion thereof of claim 38, wherein the antibody binds to the extracellular region of the polypeptide.

F8 41. The antibody or portion thereof of claim 38, wherein the antibody is a human, mouse, rat, guinea pig, rabbit, dog, cat, pig, goat, horse or cow antibody.

42. The antibody or portion thereof of claim 38, wherein the antibody is a human, mouse or rat antibody.

43. The antibody or portion thereof of claim 38, wherein the antibody is chimeric.

44. The antibody or portion thereof of claim 38, wherein the antibody is humanized.

Sub  
g1 } 45. The antibody or portion thereof of claim 38, wherein the antibody is human antibody.

46. A pharmaceutical composition comprising the antibody or portion thereof of claim 37 and a pharmaceutically acceptable carrier.

47. A pharmaceutical composition comprising the antibody or portion thereof of claim 38 and a pharmaceutically acceptable carrier.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 6

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

SUB  
H1  
48. A pharmaceutical composition comprising the antibody or portion thereof of claim 39 and a pharmaceutically acceptable carrier.

49. A pharmaceutical composition comprising the antibody or portion thereof of claim 40 and a pharmaceutically acceptable carrier.

50. A pharmaceutical composition comprising the antibody or portion thereof of claim 41 and a pharmaceutically acceptable carrier.

51. A pharmaceutical composition comprising the antibody or portion thereof of claim 42 and a pharmaceutically acceptable carrier.

F8  
52. A pharmaceutical composition comprising the antibody or portion thereof of claim 43 and a pharmaceutically acceptable carrier.

53. A pharmaceutical composition comprising the antibody or portion thereof of claim 44 and a pharmaceutically acceptable carrier.

54. A pharmaceutical composition comprising the antibody or portion thereof of claim 45 and a pharmaceutically acceptable carrier.

55. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 46.

Sub  
g2  
56. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 47.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 7

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

57. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 48.

58. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

59. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 50.

60. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 51.

61. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.

62. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 53.

63. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 54.

Applicant : Takuya Tamatani et al  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 8

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

64. A method of treating a subject suffering from or at risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 46.

65. A method of treating a subject suffering from or at risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 47.

66. A method of treating a subject suffering from or at risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 48.

67. A method of treating a subject suffering from or at risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

68. A method of treating a subject suffering from or at risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 50.

69. A method of treating a subject suffering from or at risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 51.

70. A method of treating a subject suffering from or at risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 9

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

Sub 92  
71. A method of treating a subject suffering from or at risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 53.

72. A method of treating a subject suffering from or at risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 54.

Sub 93  
H.  
73. An isolated cell that produces the antibody of claim 38.

74. An isolated cell that produces the antibody of claim 40.

F8  
75. An isolated cell that produces the antibody of claim 41.

76. An isolated cell that produces the antibody of claim 42.

77. An isolated cell that produces the antibody of claim 43.

78. An isolated cell that produces the antibody of claim 44.

Sub 93  
79. An isolated cell that produces the antibody or portion thereof of claim 45.

Sub 93  
H.  
80. A purified chimeric, humanized or human monoclonal antibody or a portion thereof that binds to a polypeptide consisting of SEQ ID NO:2.

81. The antibody or portion thereof of claim 80, wherein the antibody binds to the extracellular region of the polypeptide.

82. The antibody or portion thereof of claim 80, wherein the antibody is chimeric.

Applicant : Takuya Tamatani et al  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 10

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

83. The antibody or portion thereof of claim 80, wherein the antibody is humanized.

84. The antibody of claim 80, wherein the antibody is a human antibody.

85. A pharmaceutical composition comprising the antibody or portion thereof of claim 80 and a pharmaceutically acceptable carrier.

86. A pharmaceutical composition comprising the antibody or portion thereof of claim 81 and a pharmaceutically acceptable carrier.

87. A pharmaceutical composition comprising the antibody or portion thereof of claim 82 and a pharmaceutically acceptable carrier.

88. A pharmaceutical composition comprising the antibody or portion thereof of claim 83 and a pharmaceutically acceptable carrier.

89. A pharmaceutical composition comprising the antibody of claim 84 and a pharmaceutically acceptable carrier.

90. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 85.

91. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 86.

92. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 87.

Applicant : Takuya Tamatani et al.  
 Serial No. : 09/383,551  
 Filed : August 26, 1999  
 Page : 11

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

93. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 88.

94. A method of preventing activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 89.

95. A method of treating a subject suffering from or at a risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 85.

F8  
Sub  
94  
96. A method of treating a subject suffering from or at a risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 86.

97. A method of treating a subject suffering from or at a risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 87.

98. A method of treating a subject suffering from or at a risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 88.

99. A method of treating a subject suffering from or at a risk of glomerulonephritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 89.

Sub  
H1  
100. An isolated cell that produces the antibody of claim 80.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 12

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

- JB  
H<sub>1</sub>
101. An isolated cell that produces the antibody of claim 81.
102. An isolated cell that produces the antibody of claim 82.
103. An isolated cell that produces the antibody of claim 83.
104. An isolated hybridoma cell that produces the antibody of claim 84.
105. A process for producing a cell which secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising:
- F8
- i) immunizing a mammal with an immunogen selected from the group consisting of:
    - a) an isolated polypeptide consisting of SEQ ID NO:2;
    - b) an isolated polypeptide comprising the extracellular region of SEQ ID NO:2;
    - c) an isolated homodimer molecule consisting of two polypeptide defined in a) or two polypeptides defined in b); and
    - d) a recombinant cell transfected with a DNA encoding a polypeptide consisting of SEQ ID NO:2, wherein the cell expresses the polypeptide;
  - ii) obtaining from the mammal cells that secrete antibodies, or generating from cells of the mammal cell lines that secrete antibodies; and
  - iii) identifying from the cells obtained in ii) or from the cell lines generated in ii) a cell that secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:2.
106. The process of claim 105, wherein the antibody secreted by the cell identified in step iii) is a human antibody.
107. The process of claim 105, wherein the cell identified in step iii) is a hybridoma cell.
108. The process of claim 105, wherein the antibody secreted by the cell identified in step iii) binds to the extracellular region of the polypeptide consisting of SEQ ID NO:2.



Applicant : Takuya Tamatani et al.  
 Serial No. : 09/383,551  
 Filed : August 26, 1999  
 Page : 13

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

SUB  
H1

109. The process of claim 105, wherein the mammal is a hamster.

110. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 105, and collecting the antibody from the culture.

111. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 106, and collecting the antibody from the culture.

112. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 107, and collecting the antibody from the culture.

113. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 108, and collecting the antibody from the culture.

114. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 109, and collecting the antibody from the culture.

115. A purified non-hamster antibody or portion thereof that binds to a polypeptide consisting of SEQ ID NO:13.

116. The antibody or portion thereof of claim 115, wherein the antibody is monoclonal.

117. The antibody or portion thereof of claim 115, wherein the antibody is polyclonal.

F8

Applicant : Takuya Tamatani et al  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 14

Attorney's Docket No.: 06501-039001 / J1-802PCT-U8

JVB  
H,  
118. The antibody or portion thereof of claim 116, wherein the antibody binds to the extracellular region of the polypeptide.

119. The antibody or portion thereof of claim 116, wherein the antibody is a human, mouse, guinea pig, rabbit, dog, cat, pig, goat, horse or cow antibody.

120. The antibody or portion thereof of claim 116, wherein the antibody is a human, mouse or guinea pig antibody.

121. The antibody or portion thereof of claim 116, wherein the antibody is chimeric.

122. The antibody or portion thereof of claim 116, wherein the antibody is humanized.

F8  
123. The antibody or portion thereof of claim 116, wherein the antibody is a human antibody.

124. A pharmaceutical composition comprising the antibody or portion thereof of claim 115 and a pharmaceutically acceptable carrier.

125. A pharmaceutical composition comprising the antibody or portion thereof of claim 116 and a pharmaceutically acceptable carrier.

126. A pharmaceutical composition comprising the antibody or portion thereof of claim 117 and a pharmaceutically acceptable carrier.

127. A pharmaceutical composition comprising the antibody or portion thereof of claim 118 and a pharmaceutically acceptable carrier.

128. A pharmaceutical composition comprising the antibody or portion thereof of claim 119 and a pharmaceutically acceptable carrier.

Applicant : Takuya Tamatani et al  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 15

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

SVS  
H1  
129. A pharmaceutical composition comprising the antibody or portion thereof of claim 120 and a pharmaceutically acceptable carrier.

130. A pharmaceutical composition comprising the antibody or portion thereof of claim 121 and a pharmaceutically acceptable carrier.

131. A pharmaceutical composition comprising the antibody or portion thereof of claim 122 and a pharmaceutically acceptable carrier.

F8  
132. A pharmaceutical composition comprising the antibody or portion thereof of claim 123 and a pharmaceutically acceptable carrier.

133. An isolated cell that produces the antibody of claim 116.

134. An isolated cell that produces the antibody of claim 118.

135. An isolated cell that produces the antibody of claim 119.

136. An isolated cell that produces the antibody of claim 120.

137. An isolated cell that produces the antibody of claim 121.

138. An isolated cell that produces the antibody of claim 122.

139. An isolated cell that produces the antibody of claim 123.

140. A purified chimeric, humanized or human monoclonal antibody or a portion thereof that binds to a polypeptide consisting of SEQ ID NO:13.

Applicant : Takuya Tamatani et al  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 16

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

141. The antibody or portion thereof of claim 140, wherein the antibody binds to the extracellular region of the polypeptide.

142. The antibody or portion thereof of claim 140, wherein the antibody is chimeric.

143. The antibody or portion thereof of claim 140, wherein the antibody is humanized.

144. The antibody of claim 140, wherein the antibody is a human antibody.

145. A pharmaceutical composition comprising the antibody or portion thereof of claim 140 and a pharmaceutically acceptable carrier.

146. A pharmaceutical composition comprising the antibody or portion thereof of claim 141 and a pharmaceutically acceptable carrier.

147. A pharmaceutical composition comprising the antibody or portion thereof of claim 142 and a pharmaceutically acceptable carrier.

148. A pharmaceutical composition comprising the antibody or portion thereof of claim 143 and a pharmaceutically acceptable carrier.

149. A pharmaceutical composition comprising the antibody of claim 144 and a pharmaceutically acceptable carrier.

150. An isolated cell that produces the antibody of claim 140.

151. An isolated cell that produces the antibody of claim 141.

152. An isolated cell that produces the antibody of claim 142.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 17

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

SVB  
H<sub>1</sub> }  
153. An isolated cell that produces the antibody of claim 143.

154. An isolated hybridoma cell that produces the antibody of claim 144.

155. A process for producing a cell which secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:13, comprising:

- F8
- i) immunizing a mammal with an immunogen selected from the group consisting of:
    - a) an isolated polypeptide consisting of SEQ ID NO:13 or SEQ ID NO:15;
    - b) an isolated polypeptide comprising the extracellular region of SEQ ID NO:13 or SEQ ID NO:15;
    - c) an isolated homodimer molecule consisting of two polypeptide defined in a) or two polypeptides defined in b); and
    - d) a recombinant cell transfected with a DNA encoding a polypeptide consisting of SEQ ID NO:13 or SEQ ID NO:15, wherein the cell expresses the polypeptide;
  - ii) obtaining from the mammal cells that secrete antibodies, or generating from cells of the mammal cell lines that secrete antibodies; and
  - iii) identifying from the cells obtained in ii) or from the cell lines generated in ii) a cell that secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:13.

156. The process of claim 155, wherein the antibody secreted by the cell identified in step iii) is a human antibody.

157. The process of claim 155, wherein the cell identified in step iii) is a hybridoma cell.

158. The process of claim 155, wherein the antibody secreted by the cell identified in step iii) binds to the extracellular region of the polypeptide consisting of SEQ ID NO:13.

159. The process of claim 155, wherein the mammal is a hamster.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 18

(Attorney's Docket No.: 06501-039001 / J1-802PCT-US)

SVB  
H1  
160. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:13, comprising providing a culture of the cell identified in claim 155, and collecting the antibody from the culture.

161. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:13, comprising providing a culture of the cell identified in claim 156, and collecting the antibody from the culture.

162. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:13, comprising providing a culture of the cell identified in claim 157, and collecting the antibody from the culture.

F8  
163. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:13, comprising providing a culture of the cell identified in claim 158, and collecting the antibody from the culture.

164. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:13, comprising providing a culture of the cell identified in claim 159, and collecting the antibody from the culture.

165. A purified non-hamster antibody or portion thereof that binds to a polypeptide consisting of SEQ ID NO:14.

166. The antibody or portion thereof of claim 165, wherein the antibody is monoclonal.

167. The antibody or portion thereof of claim 165, wherein the antibody is polyclonal.

168. The antibody or portion thereof of claim 166, wherein the antibody binds to the extracellular region of the polypeptide.

Applicant : Takuya Tamatani et al  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 19

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

SJB  
H1  
169. The antibody or portion thereof of claim 166, wherein the antibody is a human, rat, guinea pig, rabbit, dog, cat, pig, goat, horse or cow antibody.

170. The antibody or portion thereof of claim 166, wherein the antibody is a human, rat or guinea pig antibody.

171. The antibody or portion thereof of claim 166, wherein the antibody is chimeric.

172. The antibody or portion thereof of claim 166, wherein the antibody is humanized.

173. The antibody or portion thereof of claim 166, wherein the antibody is a human antibody.

F8  
174. A pharmaceutical composition comprising the antibody or portion thereof of claim 165 and a pharmaceutically acceptable carrier.

175. A pharmaceutical composition comprising the antibody or portion thereof of claim 166 and a pharmaceutically acceptable carrier.

176. A pharmaceutical composition comprising the antibody or portion thereof of claim 167 and a pharmaceutically acceptable carrier.

177. A pharmaceutical composition comprising the antibody or portion thereof of claim 168 and a pharmaceutically acceptable carrier.

178. A pharmaceutical composition comprising the antibody or portion thereof of claim 169 and a pharmaceutically acceptable carrier.

179. A pharmaceutical composition comprising the antibody or portion thereof of claim 170 and a pharmaceutically acceptable carrier.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 20

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

SJS  
H1  
180. A pharmaceutical composition comprising the antibody or portion thereof of claim 171 and a pharmaceutically acceptable carrier.

181. A pharmaceutical composition comprising the antibody or portion thereof of claim 172 and a pharmaceutically acceptable carrier.

182. A pharmaceutical composition comprising the antibody or portion thereof of claim 173 and a pharmaceutically acceptable carrier.

183. An isolated cell that produces the antibody of claim 166.

184. An isolated cell that produces the antibody of claim 168.

185. An isolated cell that produces the antibody of claim 169.

186. An isolated cell that produces the antibody of claim 170.

187. An isolated cell that produces the antibody of claim 171.

188. An isolated cell that produces the antibody of claim 172.

189. An isolated cell that produces the antibody of claim 173.

190. A purified chimeric, humanized or human monoclonal antibody or a portion thereof that binds to a polypeptide consisting of SEQ ID NO:14.

191. The antibody or portion thereof of claim 190, wherein the antibody binds to the extracellular region of the polypeptide.

192. The antibody or portion thereof of claim 190, wherein the antibody is chimeric.



Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 21

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

- S13  
H1
193. The antibody or portion thereof of claim 190, wherein the antibody is humanized.
194. The antibody of claim 190, wherein the antibody is a human antibody.
195. A pharmaceutical composition comprising the antibody or portion thereof of claim 190 and a pharmaceutically acceptable carrier.
196. A pharmaceutical composition comprising the antibody or portion thereof of claim 191 and a pharmaceutically acceptable carrier.
197. A pharmaceutical composition comprising the antibody or portion thereof of claim 192 and a pharmaceutically acceptable carrier.
- F8
198. A pharmaceutical composition comprising the antibody or portion thereof of claim 193 and a pharmaceutically acceptable carrier.
199. A pharmaceutical composition comprising the antibody of claim 194 and a pharmaceutically acceptable carrier.
200. An isolated cell that produces the antibody of claim 190.
201. An isolated cell that produces the antibody of claim 191.
202. An isolated cell that produces the antibody of claim 192.
203. An isolated cell that produces the antibody of claim 193.
204. An isolated hybridoma cell that produces the antibody of claim 194.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 22

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

SVB  
H1

205. A process for producing a cell which secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising:

- i) immunizing a mammal with an immunogen selected from the group consisting of:
  - a) an isolated polypeptide consisting of SEQ ID NO:14;
  - b) an isolated polypeptide comprising the extracellular region of SEQ ID NO:14;
  - c) an isolated homodimer molecule consisting of two polypeptide defined in a) or two polypeptides defined in b); and
- d) a recombinant cell transfected with a DNA encoding a polypeptide consisting of SEQ ID NO:14, wherein the cell expresses the polypeptide;
- ii) obtaining from the mammal cells that secrete antibodies, or generating from cells of the mammal cell lines that secrete antibodies; and
- iii) identifying from the cells obtained in ii) or from the cell lines generated in ii) a cell that secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:14.

F8

206. The process of claim 205, wherein the antibody secreted by the cell identified in step iii) is a human antibody.

207. The process of claim 205, wherein the cell identified in step iii) is a hybridoma cell.

208. The process of claim 205, wherein the antibody secreted by the cell identified in step iii) binds to the extracellular region of the polypeptide consisting of SEQ ID NO:14.

209. The process of claim 205, wherein the mammal is a hamster.

210. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 205, and collecting the antibody from the culture.